OBOS Post: More Controversy Surrounding Merck and Vioxx

Yesterday at Our Bodies Our Blog, I posted a brief overview of the new debate about possible ghostwriting and data manipulation surrounding Merck and Vioxx, stemming from publications in the current issue of JAMA. Links to the freely available full-text investigations are provided, as is a timeline of Vioxx from approval to market withdrawal and beyond.